Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) just unveiled an update.
Shuttle Pharmaceuticals Holdings has finalized agreements with six cancer centers to conduct a Phase 2 clinical trial of its lead candidate, Ropidoxuridine, for treating glioblastoma, a deadly brain cancer. This trial aims to determine the optimal dosage for enhancing the effectiveness of radiation therapy. The company seeks to improve cancer cure rates and quality of life, with the trial expected to conclude in 18 to 24 months. This development presents a significant opportunity in the radiation therapy market.
See more insights into SHPH stock on TipRanks’ Stock Analysis page.
